oxymatrine has been researched along with Pancreatic Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bu, H; Chen, H; Lai, F; Lin, S; Lu, D; Luo, J; Tong, H; Wang, Z; Zhang, J; Zhang, R | 1 |
| Ling, Q; Wang, B; Wang, W; Wei, X; Xu, X; Zheng, S; Zhou, B | 1 |
2 other study(ies) available for oxymatrine and Pancreatic Neoplasms
| Article | Year |
|---|---|
Antiangiogenic effects of oxymatrine on pancreatic cancer by inhibition of the NF-κB-mediated VEGF signaling pathway.
Topics: Alkaloids; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Quinolizines; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2013 |
Oxymatrine induces human pancreatic cancer PANC-1 cells apoptosis via regulating expression of Bcl-2 and IAP families, and releasing of cytochrome c.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Growth Processes; Cell Line, Tumor; Cytochromes c; Dose-Response Relationship, Drug; Humans; Inhibitor of Apoptosis Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Quinolizines; RNA, Messenger | 2011 |